Fred Stephen Sarfo1, John Akassi2, Sheila Adamu3, Vida Obese3, Manolo Agbenorku3, Bruce Ovbiagele4. 1. Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Komfo Anokye Teaching Hospital, Kumasi, Ghana. Electronic address: stephensarfo78@gmail.com. 2. Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Komfo Anokye Teaching Hospital, Kumasi, Ghana. 3. Komfo Anokye Teaching Hospital, Kumasi, Ghana. 4. Department of Neurology, University of California, San Francisco, USA.
Abstract
BACKGROUND: Refractory hypertension (RfH) is a rare, severe phenotype of resistant hypertension, linked to higher risk of adverse cardiovascular outcomes. Little is known about the association of RfH with stroke type and subtype. OBJECTIVE: To determine the prevalence and predictors of RfH among stroke survivors in Ghana. METHODS: We interrogated the dataset of a prospectively collected registry of hypertensive patients seen between July 2015 and June 2019, at five hospitals in Ghana. We compared stroke survivors to stroke-free controls. Clinic-based blood pressure was measured using a standardized protocol and antihypertensive medications were assessed via review of medical records and inspection of pills. Refractory hypertension was defined as office BP ≥140/90 mmHg on ≥5 classes of antihypertensive medications. Multivariate logistic regression models were constructed to assess factors associated with RfH. RESULTS: Of 3927 hypertensive patients (1169 stroke survivors, 2758 controls), 86 had RfH for an overall prevalence of 2.2% (95% CI: 1.8-2.7%). Among patients with RfH, 5.8% (4.5-7.3%) were stroke survivors vs. 0.7% (0.4-1.0%) were stroke-free (p < .0001). Adjusted odds ratio (95% CI) for factors associated with RfH were being male (1.81, 1.15-2.85), age < 60 years (2.64, 1.59-4.40), chronic kidney disease (2.09, 1.21-3.60), and known stroke (7.53, 4.35-13.04). RfH was associated with intracerebral hemorrhage, (11.43, 5.65-23.14), ischemic stroke (9.76, 5.47-17.42), lacunar stroke (13.58, 6.45-28.61), and non-lacunar ischemic stroke (3.67, 1.04-13.02). CONCLUSION: Presence of RfH is significantly accentuated among stroke survivors. Intensified efforts are warranted to identify and aggressively address barriers to control in these patients to avert subsequent vascular events.
BACKGROUND: Refractory hypertension (RfH) is a rare, severe phenotype of resistant hypertension, linked to higher risk of adverse cardiovascular outcomes. Little is known about the association of RfH with stroke type and subtype. OBJECTIVE: To determine the prevalence and predictors of RfH among stroke survivors in Ghana. METHODS: We interrogated the dataset of a prospectively collected registry of hypertensivepatients seen between July 2015 and June 2019, at five hospitals in Ghana. We compared stroke survivors to stroke-free controls. Clinic-based blood pressure was measured using a standardized protocol and antihypertensive medications were assessed via review of medical records and inspection of pills. Refractory hypertension was defined as office BP ≥140/90 mmHg on ≥5 classes of antihypertensive medications. Multivariate logistic regression models were constructed to assess factors associated with RfH. RESULTS: Of 3927 hypertensivepatients (1169 stroke survivors, 2758 controls), 86 had RfH for an overall prevalence of 2.2% (95% CI: 1.8-2.7%). Among patients with RfH, 5.8% (4.5-7.3%) were stroke survivors vs. 0.7% (0.4-1.0%) were stroke-free (p < .0001). Adjusted odds ratio (95% CI) for factors associated with RfH were being male (1.81, 1.15-2.85), age < 60 years (2.64, 1.59-4.40), chronic kidney disease (2.09, 1.21-3.60), and known stroke (7.53, 4.35-13.04). RfH was associated with intracerebral hemorrhage, (11.43, 5.65-23.14), ischemic stroke (9.76, 5.47-17.42), lacunar stroke (13.58, 6.45-28.61), and non-lacunar ischemic stroke (3.67, 1.04-13.02). CONCLUSION: Presence of RfH is significantly accentuated among stroke survivors. Intensified efforts are warranted to identify and aggressively address barriers to control in these patients to avert subsequent vascular events.
Authors: Fred S Sarfo; John Akassi; Dominic Awuah; Sheila Adamu; Clara Nkyi; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2015-08-04 Impact factor: 3.181
Authors: Matthew L Flaherty; Daniel Woo; Mary Haverbusch; Padmini Sekar; Jane Khoury; Laura Sauerbeck; Charles J Moomaw; Alexander Schneider; Brett Kissela; Dawn Kleindorfer; Joseph P Broderick Journal: Stroke Date: 2005-03-24 Impact factor: 7.914
Authors: Erika S Jones; J D Spence; Adam D Mcintyre; Justus Nondi; Kennedy Gogo; Adeseye Akintunde; Daniel G Hackam; Brian L Rayner Journal: Am J Hypertens Date: 2017-05-01 Impact factor: 2.689
Authors: Valery L Feigin; Gregory A Roth; Mohsen Naghavi; Priya Parmar; Rita Krishnamurthi; Sumeet Chugh; George A Mensah; Bo Norrving; Ivy Shiue; Marie Ng; Kara Estep; Kelly Cercy; Christopher J L Murray; Mohammad H Forouzanfar Journal: Lancet Neurol Date: 2016-06-09 Impact factor: 44.182
Authors: Giovanna Bacan; Angélica Ribeiro-Silva; Vinicius A S Oliveira; Claudia R L Cardoso; Gil F Salles Journal: Curr Hypertens Rep Date: 2022-02-02 Impact factor: 5.369
Authors: Rajesh N Kalaria; Mayowa O Owolabi; Rufus O Akinyemi; Bruce Ovbiagele; Olaleye A Adeniji; Fred S Sarfo; Foad Abd-Allah; Thierry Adoukonou; Okechukwu S Ogah; Pamela Naidoo; Albertino Damasceno; Richard W Walker; Adesola Ogunniyi Journal: Nat Rev Neurol Date: 2021-09-15 Impact factor: 42.937